| |
Latest 10 SEC filings (by transaction date) for RGRX within the last 6 months | [?] |
Amended Filing Footnote and/or Remark |
Filing Date | Transaction Date | Insider Name | Ownership Type | Securities | Nature of transaction | Volume or Value | Price |
---|---|---|---|---|---|---|---|
Jul 6/23 | Jul 3/23 | Essetifin SPA | Direct Ownership | Common Stock Warrant (right to buy) | J - Other transaction | 3,750,000 | |
Jul 6/23 | Jul 3/23 | Essetifin SPA | Direct Ownership | Convertible Promissory Note (right to buy) | P - Open market or private purchase | $50,000 | $50,000.00 |
Sign up or login above to see all SEC filings within the past 6 months. |
Latest 10 SEC filings (by filing date) for RGRX within the last 6 months | [?] |
Amended Filing Footnote and/or Remark |
Filing Date | Transaction Date | Insider Name | Ownership Type | Securities | Nature of transaction | Volume or Value | Price |
---|---|---|---|---|---|---|---|
Jul 6/23 | Jul 3/23 | Essetifin SPA | Direct Ownership | Common Stock Warrant (right to buy) | J - Other transaction | 3,750,000 | |
Jul 6/23 | Jul 3/23 | Essetifin SPA | Direct Ownership | Convertible Promissory Note (right to buy) | P - Open market or private purchase | $50,000 | $50,000.00 |
Sign up or login above to see all SEC filings within the past 6 months. |
Sign up or login above to see the past 6 months of filings sorted by insider. . |
Competitors with Recent Insider Filings |
Intra-Cellular Therapies (OQ:ITCI) |
Apellis Pharmaceuticals (OQ:APLS) |
Biomarin Pharmaceutical (OQ:BMRN) |